Brigatinib is a small-molecule targeted anti-cancer therapy marketed as Alunbrig for ALK-positive non-small cell lung cancer. It inhibits ALK and additional kinase pathways and has activity in resistant disease contexts. It is a prescription oral medicine with FDA approvals in both second-line and first-line metastatic NSCLC settings.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
Mayo Clinic researchers found that Brigatinib, an FDA-approved lung cancer drug, can block survival pathways in ovarian cancer cells when combined with PARP inhibitors, potentially overcoming treatment resistance.
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06813079 |
Using Tumor Models to Determine Treatments |
RECRUITING | PHASE2 |
| NCT06532149 |
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
RECRUITING | |
| NCT06522360 |
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) |
WITHDRAWN | PHASE2 |
| NCT06132867 |
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults |
COMPLETED | PHASE1 |
| NCT05834348 |
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. |
COMPLETED | |
| NCT05721950 |
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) |
ACTIVE_NOT_RECRUITING | |
| NCT05718297 |
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer |
WITHDRAWN | PHASE2 |
| NCT05361564 |
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. |
UNKNOWN | PHASE2 |
| NCT05100069 |
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer |
RECRUITING | |
| NCT04925609 |
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
